E-mail: lling@51chemall.com
Contact Us
Wuhan Lihe New Chemical Materials Co.,Ltd
Tel:+86-027-88395717
Mob:+8613007129042
Fax:+86-027-88391805
E-mail:lling@51chemall.com
Add: Room 1801, Building B, Wuhan University Of Technology Entrepreneur Incubator, Hongshan, Wuhan, Hubei, China
Home > News > Content
The First First-line Treatment Of New Drugs In 10 Years! Eisai Weima China Listed
Nov 21, 2018

In China, Lenvima was approved in early September 2018 as a monotherapy for patients with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy. China is the country with the largest number of liver cancer patients in the world. The launch of Lenvima marks the first new systemic therapy for unresectable hepatocellular carcinoma (HCC) in China in the first 10 years.

 

Liver cancer is the second leading cause of cancer-related deaths, causing approximately 750,000 deaths worldwide each year, with 780,000 confirmed cases each year, of which about 80% occur in Asia, first China, followed by Africa. Specifically, in China, there are 395,000 new cases of liver cancer and 380,000 deaths each year, accounting for about 50% of global liver cancer cases.

 

Hepatocellular carcinoma (HCC) accounts for about 85%-90% of cases of primary liver cancer. Early stage HCC can be treated by a variety of means, including surgical resection, radiofrequency ablation, absolute ethanol injection, chemotherapy embolization, etc., but unresectable HCC is extremely refractory, treatment options are very limited, and the prognosis is extremely poor, resulting in There is a significant unmet medical need in this area. Previously, Bayer's targeted anticancer drug, Nexavar, was the only molecularly targeted drug approved for first-line treatment of unresectable HCC.

 

Lenvima's active pharmaceutical ingredient, lenvatinib, is an oral multi-receptor tyrosine kinase (RTK) inhibitor with novel binding patterns that are involved in inhibiting other pro-angiogenic and oncogenic signaling pathways involved in tumor proliferation. In addition to RTK, it is also capable of selectively inhibiting the kinase activity of the vascular endothelial growth factor (VEGF) receptor. Up to now, Lenvima has been approved by more than 50 countries including the United States, Japan, and the European Union for the treatment of refractory thyroid cancer, and more than 40 countries including the United States and the European Union have approved the combination of everolimus for the treatment of renal cell carcinoma ( RCC).

 

In March and August of this year, Lenvima was approved by Japan, the United States, and the European Union, becoming the first new first-line treatment for global advanced or unresectable HCC in the past 10 years.

 

The Chinese pharmaceutical market is the second largest market in the world after the United States. It was worth $122.2 billion in 2017 and is growing at a rate of 4%. The launch of Lenvima will further contribute to the health of liver cancer patients and their families in China.


Source From:


http://news.pharmnet.com.cn/news/2018/11/13/511609.html

Copyright © Wuhan Lihe New Chemical Materials Co.,Ltd All Rights Reserved.